Neurodegeneration – News and Features

Ichor has granted an option for RheoGene to license Ichor’s TriGrid™ Delivery System to develop proprietary therapeutics.

The consortium represents an avenue for collaborative interactions among researchers and institutional leaders from the three universities.

President’s FY07 budget calls for $40 million a year boost for multi-year effort.

Both Companies have announced license agreement for the development of a humanized monoclonal antibody 'MNAC13'.

Researchers in North America, Europe, and Asia outsource comprehensive gene expression analysis using ABI's Expression Array system.

CepTor has retained Banyan Biomarkers to develop test to evaluate effectiveness of Myodur in Muscular Dystrophy.

This is thought to be a crucial step forward for researchers who are developing drugs to combat cancer and other diseases.

Medistem has developed the method of immune response modification utilizing a genetic reprogramming technology involving RNAi.

CytRx plans to form a new subsidiary to accelerate the development and commercialization RNAi based drugs.

This versatile package can carry bits of RNA that stop the cell from expressing one of its own genes.